Theravance Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 07, 2023 at 04:05 pm EDT
Share
Theravance Biopharma, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported revenue was USD 13.75 million compared to USD 11.05 million a year ago. Net loss was USD 15.65 million compared to USD 8.19 million a year ago. Basic loss per share from continuing operations was USD 0.28 compared to USD 0.3 a year ago. Basic loss per share was USD 0.28 compared to USD 0.11 a year ago.
For the six months, revenue was USD 24.17 million compared to USD 24.25 million a year ago. Net loss was USD 37.73 million compared to USD 34.14 million a year ago. Basic loss per share from continuing operations was USD 0.63 compared to USD 0.83 a year ago. Basic loss per share was USD 0.63 compared to USD 0.45 a year ago.
Theravance Biopharma, Inc. is a biopharmaceutical company primarily focused on the development, and commercialization of medicines. Its product, YUPELRI (revefenacin) inhalation solution is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). YUPELRI is a prescription medicine used to treat COPD, a long-term lung disease that includes chronic bronchitis, emphysema, or both. YUPELRI is an anticholinergic medicine, which helps the muscles around the airway in lungs stay relaxed to prevent symptoms, such as wheezing, shortness of breath and others. Its pipeline of internally discovered programs is targeted to address unmet patient needs. Ampreloxetine, its late-stage investigational norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension. Its Selective 5-HT4 Agonist (TD-8954) is a selective 5-HT4 receptor agonist, which is developed for the treatment of gastrointestinal motility disorders.
THERAVANCE BIOPHARMA, INC. 
